Aspen has delivered double-digit earnings growth, despite a challenging trading environment characterised by inflationary cost pressures.
The pharmaceutical firm has reported a 31% increase in annual headline earnings per share and has hiked its dividend by 24% to R3.26. Business Day TV unpacked the results with Stephen Saad.